- Home
- LNW vs IONS Comparison
LNW vs IONS Comparison
Compare LNW & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNW
- IONS
- Stock Information
- Founded
- LNW 1984
- IONS 1989
- Country
- LNW United States
- IONS United States
- Employees
- LNW N/A
- IONS N/A
- Industry
- LNW EDP Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- LNW Technology
- IONS Health Care
- Exchange
- LNW Nasdaq
- IONS Nasdaq
- Market Cap
- LNW 6.7B
- IONS 6.8B
- IPO Year
- LNW N/A
- IONS 1991
- Fundamental
- Price
- LNW $79.71
- IONS $73.08
- Analyst Decision
- LNW Buy
- IONS Strong Buy
- Analyst Count
- LNW 8
- IONS 21
- Target Price
- LNW $101.88
- IONS $80.24
- AVG Volume (30 Days)
- LNW 1.4M
- IONS 2.0M
- Earning Date
- LNW 11-05-2025
- IONS 10-29-2025
- Dividend Yield
- LNW N/A
- IONS N/A
- EPS Growth
- LNW 43.14
- IONS N/A
- EPS
- LNW 4.59
- IONS N/A
- Revenue
- LNW $3,221,000,000.00
- IONS $966,957,000.00
- Revenue This Year
- LNW $7.18
- IONS $27.96
- Revenue Next Year
- LNW $7.61
- IONS $2.33
- P/E Ratio
- LNW $17.35
- IONS N/A
- Revenue Growth
- LNW 1.87
- IONS 20.41
- 52 Week Low
- LNW $69.56
- IONS $23.95
- 52 Week High
- LNW $113.95
- IONS $76.78
- Technical
- Relative Strength Index (RSI)
- LNW 55.32
- IONS 59.20
- Support Level
- LNW $73.11
- IONS $71.48
- Resistance Level
- LNW $86.00
- IONS $76.78
- Average True Range (ATR)
- LNW 2.30
- IONS 2.32
- MACD
- LNW 0.91
- IONS -0.42
- Stochastic Oscillator
- LNW 58.20
- IONS 43.52
About LNW Light & Wonder Inc.
Light & Wonder is principally an electronic gaming machine manufacturer, selling machines to pubs, clubs, and casinos. The firm is licensed in most jurisdictions allowing gambling globally. Light & Wonder is one of the three largest players in the space along with International Game Technology and Aristocrat Leisure. SciPlay, about one fourth of revenue, develops and distributes casual mobile games, principally in the social casino niche. The more nascent iGaming business sits between these two businesses, providing digital content and capabilities to real-money gaming providers.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.